Literature DB >> 23086987

A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia.

Dawn Velligan1, Jim Mintz, Natalie Maples, Li Xueying, Stephanie Gajewski, Heather Carr, Cynthia Sierra.   

Abstract

Poor adherence to medication leads to symptom exacerbation and interferes with the recovery process for patients with schizophrenia. Following baseline assessment, 142 patients in medication maintenance at a community mental health center were randomized to one of 3 treatments for 9 months: (1) PharmCAT, supports including pill containers, signs, alarms, checklists and the organization of belongings established in weekly home visits from a PharmCAT therapist; (2) Med-eMonitor (MM), an electronic medication monitor that prompts use of medication, cues the taking of medication, warns patients when they are taking the wrong medication or taking it at the wrong time, record complaints, and, through modem hookup, alerts treatment staff of failures to take medication as prescribed; (3) Treatment as Usual (TAU). All patients received the Med-eMonitor device to record medication adherence. The device was programmed for intervention only in the MM group. Data on symptoms, global functioning, and contact with emergency services and police were obtained every 3 months. Repeated measures analyses of variance for mixed models indicated that adherence to medication was significantly better in both active conditions than in TAU (both p<0.0001). Adherence in active treatments ranged from 90-92% compared to 73% in TAU based on electronic monitoring. In-person and electronic interventions significantly improved adherence to medication, but that did not translate to improved clinical outcomes. Implications for treatment and health care costs are discussed.

Entities:  

Keywords:  cognitive adaptation; electronic adherence intervention; environmental supports; medication adherence; medication compliance; pill containers; smart; training

Mesh:

Substances:

Year:  2012        PMID: 23086987      PMCID: PMC3756784          DOI: 10.1093/schbul/sbs116

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  19 in total

1.  Centring in regression analyses: a strategy to prevent errors in statistical inference.

Authors:  Helena C Kraemer; Christine M Blasey
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

Review 2.  Size of treatment effects and their importance to clinical research and practice.

Authors:  Helena Chmura Kraemer; David J Kupfer
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

3.  Brief psychiatric rating scale expanded version: How do new items affect factor structure?

Authors:  Dawn Velligan; Thomas Prihoda; Ellen Dennehy; Melanie Biggs; Kathy Shores-Wilson; M Lynn Crismon; A John Rush; Alexander Miller; Trisha Suppes; Madhukar Trivedi; T Michael Kashner; Bradley Witte; Marcia Toprac; Thomas Carmody; John Chiles; Stephen Shon
Journal:  Psychiatry Res       Date:  2005-06-30       Impact factor: 3.222

4.  The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.

Authors:  Dawn I Velligan; Pamela M Diamond; Jim Mintz; Natalie Maples; Xueying Li; John Zeber; Larry Ereshefsky; Yui-Wing F Lam; Desiree Castillo; Alexander L Miller
Journal:  Schizophr Bull       Date:  2007-10-10       Impact factor: 9.306

Review 5.  Understanding and addressing adherence issues in schizophrenia: from theory to practice.

Authors:  Peter J Weiden
Journal:  J Clin Psychiatry       Date:  2007       Impact factor: 4.384

6.  Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale.

Authors:  J Ventura; K H Nuechterlein; K L Subotnik; D Gutkind; E A Gilbert
Journal:  Psychiatry Res       Date:  2000-12-27       Impact factor: 3.222

7.  Antipsychotic medication adherence: is there a difference between typical and atypical agents?

Authors:  Christian R Dolder; Jonathan P Lacro; Laura B Dunn; Dilip V Jeste
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

Review 8.  Rehabilitation and recovery in schizophrenia.

Authors:  Dawn I Velligan; Jodi M Gonzalez
Journal:  Psychiatr Clin North Am       Date:  2007-09

9.  Preliminary evaluation of cognitive adaptation training to compensate for cognitive deficits in schizophrenia.

Authors:  D I Velligan; R K Mahurin; J E True; R S Lefton; C V Flores
Journal:  Psychiatr Serv       Date:  1996-04       Impact factor: 3.084

Review 10.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

View more
  22 in total

1.  Practical strategies for improving adherence to medication and outcomes.

Authors:  Dawn I Velligan; Martha Sajatovic
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

2.  Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.

Authors:  Jimmi Nielsen; Signe O W Jensen; Rasmus B Friis; Jan B Valentin; Christoph U Correll
Journal:  Schizophr Bull       Date:  2014-09-01       Impact factor: 9.306

3.  Compensatory Interventions for Cognitive Impairments in Psychosis: A Systematic Review and Meta-Analysis.

Authors:  Kelly Allott; Kristi van-der-El; Shayden Bryce; Emma M Parrish; Susan R McGurk; Sarah Hetrick; Christopher R Bowie; Sean Kidd; Matthew Hamilton; Eoin Killackey; Dawn Velligan
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

4.  Predictors of Hospitalization of Individuals With First-Episode Psychosis: Data From a 2-Year Follow-Up of the RAISE-ETP.

Authors:  Delbert G Robinson; Nina R Schooler; Robert A Rosenheck; Haiqun Lin; Kyaw J Sint; Patricia Marcy; John M Kane
Journal:  Psychiatr Serv       Date:  2019-05-14       Impact factor: 3.084

5.  Development and Feasibility Testing of a Smartphone Intervention to Improve Adherence to Antipsychotic Medications.

Authors:  Julie Kreyenbuhl; Elizabeth J Record; Seth Himelhoch; Melanie Charlotte; Jessica Palmer-Bacon; Lisa B Dixon; Deborah R Medoff; Lan Li
Journal:  Clin Schizophr Relat Psychoses       Date:  2016-07-25

6.  Validation of a Computerized test of Functional Capacity.

Authors:  Richard S E Keefe; Vicki G Davis; Alexandra S Atkins; Adam Vaughan; Tom Patterson; Meera Narasimhan; Philip D Harvey
Journal:  Schizophr Res       Date:  2016-04-16       Impact factor: 4.939

Review 7.  Strategies to improve medication adherence in patients with schizophrenia: the role of support services.

Authors:  Peggy El-Mallakh; Jan Findlay
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-16       Impact factor: 2.570

Review 8.  Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.

Authors:  Peter M Haddad; Cecilia Brain; Jan Scott
Journal:  Patient Relat Outcome Meas       Date:  2014-06-23

Review 9.  Medication nonadherence and psychiatry.

Authors:  Sarah C E Chapman; Rob Horne
Journal:  Curr Opin Psychiatry       Date:  2013-09       Impact factor: 4.741

10.  The Daily Activity Report (DAR) a Novel Measure of Functional Outcome for Serious Mental Illness.

Authors:  Dawn I Velligan; Jim Mintz; Cynthia Sierra; Mona L Martin; Megan Fredrick; Gregory A Maglinte; Patricia K Corey-Lisle
Journal:  Schizophr Bull       Date:  2015-12-27       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.